CD274 and non-small cell lung carcinoma: Among patients with stage II-IIIA PD-L1 positive NSCLC, DFS favored Atezolizumab in both age groups: HR 0.67 (0.46–0.96) in those aged < 65 years; HR 0.64 (0.41–1.01) in those aged ≥65 years.